NMED 724

Drug Profile

NMED 724

Latest Information Update: 25 Mar 2008

Price : $50

At a glance

  • Originator Neuromed Pharmaceuticals
  • Class Antimigraines
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 25 Mar 2008 Discontinued - Preclinical for Migraine in Canada (unspecified route)
  • 08 Mar 2006 Neuromed Technologies is now called Neuromed Pharmaceuticals
  • 29 Oct 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top